1. Introduction {#sec1}
===============

Although mortality from cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell transplantation (alloHSCT) has largely decreased with modern preemptive treatment, CMV viremias still contribute to significant morbidity and a considerable hospitalization burden for intravenous therapy with the standard first-line CMV drugs ganciclovir (GCV) and foscarnet (FCN).

Valganciclovir (VGC), an orally available prodrug hydrolyzed to GCV, with a tenfold bioavailability compared to oral GCV \[[@B1]\], has been licensed for therapy of CMV retinitis in HIV disease and for CMV prophylaxis after solid organ transplantation, but not after alloHSCT, due to concern about its myelotoxicity, especially in long-term application. However, VGC has enjoyed widespread off-label use thanks to its outpatient applicability and its excellent bioavailability even in patients with impaired resorption due to intestinal graft-versus-host disease \[[@B2]--[@B4]\]. Several smaller trials and one large study found high efficacy (73%--100%) of VGC in the preemptive setting after alloHSCT (\[[@B5]--[@B14]\]; see [Table 1](#tab1){ref-type="table"}), comparing favourably with standard CMV drugs. However, these mostly retrospective studies with short follow up may have underestimated toxicity, although some of them reported up to 27% severe hematotoxicity, especially neutropenia.

Here, we present the largest single-center study to date on VGC in preemptive treatment of CMV viremias after alloHSCT, assessing the neutropenia risk of VGC in a well-sized retrospective cohort and evaluating a prospective surveillance strategy to improve safety in outpatient VGC therapy.

2. Patients and Methods {#sec2}
=======================

2.1. Study Design {#sec2.1}
-----------------

This is a combined retrospective and prospective comparative cohort study, analyzing all consecutive CMV viremias after alloHSCT treated preemptively at our institution during the years 1996 through 2006 (retrospective cohort 1: 169 patients; 312 CMV viremias) as well as 2007 through 2011 (prospective cohort 2: 118 patients; 202 CMV viremias). Excluded were patients originally not allotransplanted at our institution and patients without details on CMV treatment at other hospitals. Data are as of July 1st, 2012, thus allowing for at least six months of follow up. Patient data evaluation was in complete concordance with the declaration of Helsinki. All patients had given written informed consent prior to transplantation; prior to preemptive CMV therapy, informed consent was again obtained.

2.2. Diagnosis and Preemptive Treatment of CMV Viremias {#sec2.2}
-------------------------------------------------------

According to our institutional standard operating procedures, every patient after alloHSCT was followed weekly until immune reconstitution by CMV pp65 antigen testing or, during neutropenia, by CMV DNA PCR. Preemptive therapy was started when a significant increase of CMV pp65 antigen was noted (generally more than 5 per 400.000 leukocytes positive or CMV DNA PCR exceeding 10.000 copies per mL whole blood). Preemptive therapy of CMV viremias was selected according to the patients\' toxicity profile: GCV in case of renal impairment, FCN if hematopoietic reconstitution was yet insufficient. Patients without hematopoietic or renal compromise were given the choice between intravenous GCV and oral VGC, after counseling about side effects of both drugs as well as about the off-label status of VGC. Standard doses of VGC (900 mg every 12 hours), GCV (5 mg per kg body weight every 12 hours), FCN (90 mg per kg body weight every 12 hours), or cidofovir (CDF; 5 mg per kg body weight once a week, but not as first-line therapy) were used with appropriate hydration and supportive measures and tailored according to renal function, as detailed in the manufacturers\' descriptions. Initial preemptive therapy was given for at least two weeks (or changed to a second-line drug if viremia progressed); it was stopped after three consecutive negative CMV tests.

Patients were documented in the "VGC group" if they had received VGC at any time during a CMV viremia episode, if not, they belonged to the "non-VGC group."

In cohort 1, maintenance therapy was used, mostly at half the initial dose, in patients with unfavourable CMV constellation (recipient positive/donor negative; R+/D−) and in patients with repeated CMV viremias. In cohort 2, maintenance treatment was avoided, whenever possible, in order to prevent profound neutropenias. Patients in cohort 2 who opted for outpatient VGC were instructed to have complete blood counts controlled twice a week for early detection of neutropenia.

2.3. Patient Cohorts {#sec2.3}
--------------------

Both cohorts are described in detail in [Table 2](#tab2){ref-type="table"}. In cohort 1, despite the retrospective study design, both the VGC and the non-VGC group were comparable for demographic, disease- and transplant-related aspects such as gender, diagnosis, and donor type. However, VGC patients of cohort 1 were generally older, had more advanced disease, showed more often the unfavourable CMV constellation R+/D−, and more of them had received reduced intensity conditioning and *in vivo* T cell depletion with antithymocyte globulin (ATG). In contrast, the VGC and the non-VGC groups of cohort 2 were much better balanced with respect to all demographic, disease- and transplant-related characteristics, even conditioning and *in vivo* T cell depletion, but especially age and disease status which were considerably less favourable in both groups of cohort 2 compared to cohort 1. Thus, a historical trend is evident towards alloHSCT in patients of ever increasing age and morbidity.

2.4. Statistics {#sec2.4}
---------------

Due to the retrospective design of cohort 1, statistics were primarily descriptive. Statistical comparisons were calculated from cross-tables employing two-sided Chi-square tests.

3. Results and Discussion {#sec3}
=========================

3.1. Efficacy of VGC in Preemptive Therapy of CMV Viremias {#sec3.1}
----------------------------------------------------------

In cohort 1, the rate of CMV clearance was better for patients preemptively treated with VGC (79%) than with non-VGC therapies (69%), *P* = 0.04. In cohort 2, efficacy was similar in both groups: VGC cleared CMV viremia in 71%, non-VGC treatments in 72% (not significant). These results are in concordance with and confirm published studies (see [Table 1](#tab1){ref-type="table"}).

3.2. Hospitalization Requirements for VGC versus Non-VGC Preemptive Therapies {#sec3.2}
-----------------------------------------------------------------------------

As expected, hospitalization for preemptive therapy was lower in VGC-treated patients. However, in cohort 1, severe neutropenias in the VGC group accounted for prolonged subsequent rehospitalizations. Thus, when considering both initial preemptive therapy and later treatment of complications, there was no difference between the groups in mean total hospitalisation (cohort 1: VGC 8 days (0--257); non-VGC 10 days (0--89); not significant). Of course, as suggested by the wide range of hospitalization duration in the VGC group of cohort 1, few outliers with excessive subsequent rehospitalizations (see [Section 3.3](#sec3.3){ref-type="sec"}) were responsible for this statistical effect which, however, highlights well the potential danger from VGC treatment in terms of profound and prolonged myelotoxicity.

This observation led us to implement frequent neutrophil monitoring during outpatient VGC treatment in cohort 2. Here, likely as a consequence of our change in surveillance strategy, we were able to demonstrate a reduced mean duration of total hospitalization after VGC (9 days (0--66)) as compared to non-VGC therapies (25 days (0--115)), with a much narrower range in the VGC group ([Figure 1](#fig1){ref-type="fig"}).

Surprisingly, mean hospitalization in the non-VGC groups differed substantially between cohorts 1 and 2. A potential explanation for this may derive from the significant differences between both cohorts, especially regarding patient age, disease risk, and mismatched donors. Compared to cohort 1, where the non-VGC group enjoyed greatly favourable characteristics with respect to the VGC group, in cohort 2, both groups were strongly disadvantaged; thus, patients may have suffered more toxicities from non-VGC therapies, too. Other possible factors for differences between the cohorts include toxicities from concomitant medications which might have been unequally distributed in consecutive cohorts. Finally, the possibility should be considered that prevalent CMV strains were becoming increasingly resistant over time; thus, more patients might have required additional CMV therapies.

3.3. Myelotoxicity of VGC in Preemptive CMV Treatment after AlloHSCT {#sec3.3}
--------------------------------------------------------------------

In cohort 1, although numerically comparable (11% in both the VGC and the non-VGC group), severe neutropenias were of greater clinical importance in the VGC group, compatible with a more profound and/or prolonged suppressive effect of VGC on granulopoiesis \[[@B2]\]. Especially, two cases of agranulocytosis occurred, which were confirmed by bone marrow biopsy. Whereas one patient recovered with granulocyte-colony stimulating factor after more than one month of hospitalization, the other patient additionally experienced a complete loss of his graft, eventually requiring retransplantation 6 months after preemptive VGC therapy; unfortunately, he died 4.5 months after the second transplant from infectious complications.

In cohort 2, neutropenias occurred in significant less patients of the VGC group (*n* = 9) than in patients of the non-VGC group (*n* = 37), *P* = 0.004. Conversely, the duration of neutropenias was not different (VGC: median 8 days, range 1--14; non-VGC: median 7 days, range 1--34; not significant). No cases of agranulocytosis or graft loss were observed in cohort 2.

Suppression of granulopoiesis was the most clinically relevant myelotoxicity of VGC encountered in our cohorts. When we compared frequencies of anemia, thrombocytopenia, red blood cell transfusion, and platelet substitution, we could not detect any significant differences in either cohort (data not shown).

3.4. Strengths and Limitations of the Study {#sec3.4}
-------------------------------------------

The main limitations of this study are the retrospective design of cohort 1 and the difficulty to directly compare both cohorts due to the differences between them; however, the comparisons within each cohort still remain unchallenged. Another shortcoming is the nonrandomized treatment allocation, introducing a patient\'s bias with the patient\'s choice; however, this may better reflect real clinical practice in preemptive therapy of CMV viremias after alloHSCT.

Strengths of this study are its well-sized cohorts, making it the currently largest study with the longest follow up on VGC in the preemptive setting after alloHSCT. It is thus suited for the detection of rare, but severe, events and appropriate for assessment of a surveillance strategy to improve the safety of treatment with this widely used, but narrowly evaluated, yet unlicensed drug.

4. Conclusions {#sec4}
==============

The present study combines adequately sized retrospective and prospective cohorts to examine the significant neutropenia risk of VGC for CMV viremia in the preemptive setting after alloHSCT. We show that outpatient VGC therapy can be safely applied in these patients, following a simple surveillance strategy with frequent neutrophil monitoring and using VGC maintenance therapy with utmost caution.

Further large, prospective studies on the use of VGC after alloHSCT are welcome.
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###### 

Studies on VGC in the preemptive setting after alloHSCT.

  -----------------------------------------------------------------------------------------------------------------------------------------
  Author\                                    Design           *N* patients   VGC dose            VGC efficacy   Toxicity reported
  year \[ref.\]                                                                                                 
  ------------------------------------------ ---------------- -------------- ------------------- -------------- ---------------------------
  van der Heiden et al. 2006 \[[@B5]\]       Retrospective\   34             1800 mg/d           80%            None
                                             VGC/GCV                                                            

  Ayala et al. 2006 \[[@B6]\]                Retrospective\   18             1800 mg/d ×  14,\   93%            None
                                             VGC mono                        → 900 mg/d × ≥7                    

  Busca et al. 2007 \[[@B7]\]                Retrospective\   15             1800 mg/d × 14,\    73%            27% severe hematotoxicity
                                             VGC mono                        → 900 mg/d × 14                    

  Candoni et al. 2008 \[[@B8]\]              Retrospective\   30             1800 mg/d\          93%\           ≤WHO °II
                                             VGC mono                        versus 900 mg/d     87%            

  de la Cruz-Vicente et al. 2008 \[[@B9]\]   Prospective\     11             1800 mg/d × 14,\    100%           None
                                             VGC/GCV                         → 900 mg/d × 14                    

  Wang et al. 2008 \[[@B10]\]                Retrospective\   19             1800 mg/d × 14,\    95%            None
                                             VGC mono                        → 900 mg/d × 14                    

  Takenaka et al. 2009 \[[@B11]\]            Retrospective\   10             1800 mg/d × 21      90%            10% severe neutropenias
                                             VGC mono                                                           

  Saleh et al. 2010 \[[@B12]\]               Retrospective\   47             1800 mg/d ×≥7,\     97%            17% severe neutropenias
                                             VGC mono                        → 900 mg/d ×≥7                     

  Palladino et al. 2010 \[[@B13]\]           Retrospective\   34             1800 mg/d\          100%\          None
                                             VGC mono                        versus 900 mg/d     83%            

  Liu et al. 2010 \[[@B14]\]                 Prospective\     54             1800 mg/d × 14,\    89%            None
                                             VGC mono                        → 900 mg/d × 14                    

  Ruiz-Camps et al. 2011 \[[@B15]\]          Prospective\     166                                91%            5% adverse events
                                             VGC/GCV                                                            
  -----------------------------------------------------------------------------------------------------------------------------------------

###### 

Patient cohorts of preemptive therapy for CMV viremias.

                         Cohort 1 (1996--2006)   Cohort 2 (2007--2011)                               
  ---------------------- ----------------------- ----------------------- --------- -------- -------- ------
  *N* patients           79                      90                      ---       48       70       ---
  *N* viremias           165                     147                     ---       67       135      ---
  Gender                                                                                              
   Female                .44                     .44                     n.s.      .50      .47      n.s.
   Male                  .56                     .56                     .50       .53               
  Age                                                                                                 
   Median                50                      43                      \<0.001   53       56       n.s.
   Range                 18--68                  18--65                            20--67   19--72    
  Diagnosis                                                                                           
   Nonmalignant          .03                     .00                     n.s.      .03      .04      n.s.
   Chronic malignancy    .24                     .26                     .17       .32               
   Acute malignancy      .73                     .74                     .80       .64               
  Disease risk                                                                                        
   Standard              .29                     .47                     \<0.05    .11      .23      n.s.
   Advanced              .71                     .53                     .89       .77               
  Donor                                                                                               
   Matched related       .28                     .43                     n.s.      .25      .21      n.s.
   Matched unrelated     .68                     .52                     .44       .53               
   Mismatched            .04                     .05                     .31       .26               
  CMV                                                                                                 
   R−/D−, R−/D+, R+/D+   .51                     .67                     \<0.05    .69      .70      n.s.
   R+/D−                 .49                     .33                     .31       .30               
  Conditioning                                                                                        
   Reduced intensity     .65                     .30                     \<0.001   .83      .79      n.s.
   Myeloablative         .35                     .70                     .17       .21               
  T cell depletion                                                                                    
   None                  .11                     .40                               .06      .08      n.s.
    *In vivo* (ATG)      .84                     .44                     \<0.001   .94      .92      
    *In vitro*           .05                     .16                               .00      .00      
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